A Phase 1 interventional study of LY3502970 and Esomeprazole in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to assess how fast LY3502970 gets into the blood stream and how long it takes the body to remove it when administered in multiple oral doses as new formulation compared to that of reference LY3502970 formulation. Information about safety and tolerability will be collected. The study is open to healthy participants. The study is conducted in two parts and it will last up to about 6 months, inclusive of screening period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received single escalating doses of LY3502970 oral capsule every 6 days, starting with a dose of 2 milligrams (mg), increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19. * Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 reference oral capsule once daily (QD) * Test Phase/Fasted state (Day 25 to Day 36): On Day 25, participants were randomly assigned to receive 16 mg of LY3502970 QD, either as Prototype 1 tablet or Prototype 2 tablet, and continued through Day 30 (Test Phase 1). On Day 31, participants crossover to the other prototype formulation (i.e., those who initially received prototype 1 now receive prototype 2, and vice versa), continuing through Day 36 (Test Phase 2).
Drug: LY3502970
* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received single escalating doses of LY3502970 oral capsule every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19. * Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 prototype 2 tablet QD. * Test Phase 1/Fed state (Day 25 to Day 30): During this phase, participants were administered 16 mg of LY3502970 prototype 2 tablet QD. * Test Phase 2/Fasted state (Day 31 to Day 36): During this phase, participants were administered a PPI 40 mg Esomeprazole tablet first, followed by 16 mg of LY3502970 prototype 2 tablet QD. The PPI was administered to elevate gastric pH (potential of hydrogen), and PK (pharmacokinetic) parameters were evaluated under these elevated gastric pH conditions
Drug: LY3502970 · Drug: Esomeprazole
Administered orally.
Administered orally.
Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
Part A: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Part A: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-Dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
Part A: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
Part A: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
Part B: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Part B: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
Part B: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
Part B: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.
Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
The study was conducted in 2 parts: Part A: This is the initial formulation evaluation phase, where multiple oral doses of LY3502970 formulation prototypes were tested in a group of participants. Part B: This is the secondary evaluation phase in another group of participants, where, depending on the results of Part A, one of the prototypes may be further evaluated with regard to the effects of food, proton pump inhibitors (PPIs), or additional prototype formulations may be explored.
| Milestone | Part A | Part B |
|---|---|---|
| Started | 12 | 14 |
| Received at least 1 dose of study drug (safety analyses set) | 12 | 14 |
| Completed | 10 | 12 |
| Not completed | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Adverse event | 0 | 2 |
Part A: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).
| nanograms per milliliter (ng/mL) | Part A (LY3502970) |
|---|---|
| 16 mg reference capsule (Day 24) | 66.2 ± 77.4 |
| 16 mg prototype 1 tablet (Days 30 and 36) | 111 ± 81.2 |
| 16 mg prototype 2 tablet (Days 30 and 36) | 97.4 ± 58.9 |
Part A: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).
| nanogram*hours per milliliter (ng*h/mL) | Part A (LY3502970) |
|---|---|
| 16 mg reference capsule (Day 24) | 988 ± 66.9 |
| 16 mg prototype 1 tablet (Days 30 and 36) | 1480 ± 75.2 |
| 16 mg prototype 2 tablet (Days 30 and 36) | 1400 ± 51.2 |
Part A: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).
| hours | Part A (LY3502970) |
|---|---|
| 16 mg reference capsule (Day 24) | 7.02 (4 to 8) |
| 16 mg prototype 1 tablet (Days 30 and 36) | 8 (4 to 16) |
| 16 mg prototype 2 tablet (Days 30 and 36) | 8 (4 to 16) |
Part B: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.
| ng/mL | Part B |
|---|---|
| 16 mg prototype 2 tablet (Fasted) (Day 24) | 63.4 ± 32.2 |
| 16 mg prototype 2 tablet (Fed) (Day 30) | 56.3 ± 29.6 |
| 16 mg Prototype 2 tablet + PPI (Fasted) (Day 36) | 59.6 ± 51.0 |
Part B: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.
| ng*h/mL | Part B |
|---|---|
| 16 mg prototype 2 tablet (Fasted) (Day 24) | 903 ± 25.3 |
| 16 mg prototype 2 tablet (Fed) (Day 30) | 865 ± 24.6 |
| 16 mg Prototype 2 tablet + PPI (Fasted) (Day 36) | 956 ± 40.1 |
Part B: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.
| hours | Part B |
|---|---|
| 16 mg prototype 2 tablet (Fasted) (Day 24) | 8.00 (4.00 to 12.00) |
| 16 mg prototype 2 tablet (Fed) (Day 30) | 7.00 (2.00 to 16.05) |
| 16 mg Prototype 2 tablet + PPI (Fasted) (Day 36) | 7.00 (4.00 to 12.00) |
Collected over Baseline to the end of follow-up (up to Day 53). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - 2 mg Capsule | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Part A - 4 mg Capsule | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Part A - 8 mg Capsule | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Part A - 16 mg Capsule | 0/11 (0%) | 0/11 (0%) | 11/11 (100%) |
| Part A - 16 mg Prototype 1 Tablet | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Part A - 16 mg Prototype 2 Tablet | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Part B - 2 mg Capsule | 0/14 (0%) | 0/14 (0%) | 13/14 (92.9%) |
| Part B - 4 mg Capsule | 0/14 (0%) | 0/14 (0%) | 12/14 (85.7%) |
| Part B - 8 mg Capsule | 0/14 (0%) | 0/14 (0%) | 13/14 (92.9%) |
| Part B -16 mg Prototype 2 Tablet/Fasted | 0/14 (0%) | 0/14 (0%) | 12/14 (85.7%) |
| Part B - 16 mg Prototype 2 Tablet/Fed | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Part B - 16 mg Prototype 2 Tablet + PPI | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Event | Part A - 2 mg Capsule | Part A - 4 mg Capsule | Part A - 8 mg Capsule | Part A - 16 mg Capsule | Part A - 16 mg Prototype 1 Tablet | Part A - 16 mg Prototype 2 Tablet | Part B - 2 mg Capsule | Part B - 4 mg Capsule | Part B - 8 mg Capsule | Part B -16 mg Prototype 2 Tablet/Fasted | Part B - 16 mg Prototype 2 Tablet/Fed | Part B - 16 mg Prototype 2 Tablet + PPI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 7/12 | 6/12 | 6/12 | 8/11 | 5/10 | 6/10 | 7/14 | 3/14 | 3/14 | 4/14 | 3/12 | 1/12 |
| Weight decreasedInvestigations | 0/12 | 0/12 | 8/12 | 0/11 | 0/10 | 0/10 | 0/14 | 0/14 | 3/14 | 3/14 | 1/12 | 1/12 |
| ConstipationGastrointestinal disorders | 5/12 | 1/12 | 4/12 | 3/11 | 0/10 | 0/10 | 7/14 | 3/14 | 3/14 | 1/14 | 1/12 | 1/12 |
| HeadacheNervous system disorders | 6/12 | 3/12 | 4/12 | 2/11 | 3/10 | 0/10 | 4/14 | 2/14 | 0/14 | 4/14 | 1/12 | 1/12 |
| Decreased appetiteMetabolism and nutrition disorders | 5/12 | 2/12 | 3/12 | 0/11 | 0/10 | 0/10 | 6/14 | 2/14 | 2/14 | 0/14 | 1/12 | 0/12 |
| Abdominal distensionGastrointestinal disorders | 4/12 | 1/12 | 1/12 | 1/11 | 2/10 | 1/10 | 4/14 | 1/14 | 0/14 | 0/14 | 1/12 | 1/12 |
| VomitingGastrointestinal disorders | 4/12 | 0/12 | 1/12 | 2/11 | 1/10 | 1/10 | 4/14 | 0/14 | 0/14 | 2/14 | 1/12 | 0/12 |
| FatigueGeneral disorders | 1/12 | 0/12 | 0/12 | 0/11 | 3/10 | 0/10 | 1/14 | 0/14 | 0/14 | 0/14 | 0/12 | 0/12 |
| DysgeusiaNervous system disorders | 0/12 | 0/12 | 2/12 | 1/11 | 3/10 | 0/10 | 1/14 | 0/14 | 0/14 | 0/14 | 0/12 | 0/12 |
| Abdominal discomfortGastrointestinal disorders | 0/12 | 1/12 | 2/12 | 2/11 | 0/10 | 0/10 | 0/14 | 0/14 | 3/14 | 3/14 | 1/12 | 0/12 |
All participants who received at least one dose of study drug.
| Age, Categorical(Participants) | Part A (LY3502970) | Part B (LY3502970) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 14 | 26 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A (LY3502970) | Part B (LY3502970) | Total |
|---|---|---|---|
| Female | 3 | 1 | 4 |
| Male | 9 | 13 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Part A (LY3502970) | Part B (LY3502970) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 14 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A (LY3502970) | Part B (LY3502970) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 11 | 14 | 25 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Apr 2022, 6 months.
Results were first posted in May 2026, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron